Fish oil supplementation does not lower C-reactive protein or interleukin-6 levels in healthy adults
| Autor: | Susan M. Sereika, Dora C.-H. Kuan, Anna L. Marsland, Bahar Laderian, Stephen B. Manuck, Matthew F. Muldoon |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Docosahexaenoic Acids 030204 cardiovascular system & hematology Systemic inflammation Article 03 medical and health sciences Fish Oils 0302 clinical medicine Internal medicine Internal Medicine Humans Medicine Interleukin 6 chemistry.chemical_classification biology Interleukin-6 business.industry C-reactive protein Interleukin Middle Aged Fish oil Eicosapentaenoic acid C-Reactive Protein Endocrinology Eicosapentaenoic Acid chemistry Docosahexaenoic acid Dietary Supplements Immunology biology.protein Female lipids (amino acids peptides and proteins) medicine.symptom business 030217 neurology & neurosurgery Polyunsaturated fatty acid |
| Zdroj: | Journal of Internal Medicine. 279:98-109 |
| ISSN: | 0954-6820 |
| DOI: | 10.1111/joim.12442 |
| Popis: | Background The n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may prevent a range of chronic conditions through anti-inflammatory actions. However, as clinical trials using these fatty acids for primary prevention are yet unavailable, their putative role in disease prevention rests, in part, on evidence of anti-inflammatory actions in healthy individuals. Objective To investigate in a double-blind, placebo-controlled clinical trial whether supplementation with a moderate dose of EPA+DHA reduces common biomarkers of chronic, systemic inflammation in healthy individuals. Methods A total of 261 healthy individuals aged 30–54 years who were free of inflammatory conditions and consumed ≤300 mg per day EPA+DHA were included in the study. Participants were randomly assigned to 18 weeks of either fish oil supplementation providing 1400 mg per day EPA+DHA or matching placebo. Outcome measures were serum levels of C-reactive protein (CRP) and interleukin (IL)-6. In a substudy, ex vivo cytokine production was measured. Missing data for CRP and IL-6 were estimated using regression imputation. Data analyses conformed to intention-to-treat principles. Results Participant blinding was verified. Red blood cell EPA+DHA increased by 64% in the active treatment group, but serum CRP and IL-6 were not affected by supplementation (P ≥ 0.20). Findings were consistent with and without imputed values and across subgroups. Similarly, EPA+DHA supplementation did not alter ex vivo production of four pro-inflammatory cytokines (P ≥ 0.20). Conclusions Supplementation with 1400 mg EPA+DHA did not reduce common markers of systemic inflammation in healthy adults. Whether this or a higher dose affects other measures of inflammation, oxidative stress or immune function warrants examination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text